Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | terminated | Phase 1 / Phase 2 | 41 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT04488003 | Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations | terminated | Phase 2 | 104 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Jun 4, 2024 |
| NCT04618393 | A Study of EMB-02 in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 47 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 3 | May 21, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours(MYCure) | terminated | Phase 1 / Phase 2 | 22 | Peptomyc S.L.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05581719 | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | terminated | Phase 1 / Phase 2 | 14 | Enlivex Therapeutics RDO Ltd.INDUSTRY | 2 | Apr 17, 2024 | clinicaltrials |
| NCT05148533 | A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor | terminated | Phase 1 / Phase 2 | 7 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT02920996 | Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05071183 | A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 9 | Turning Point Therapeutics, Inc.INDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04172597 | A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies | terminated | Phase 2 | 1 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05148195 | A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors | terminated | Phase 2 | 86 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT05357898 | Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 20 | SQZ BiotechnologiesINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03461952 | Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)(NIMBLe) | terminated | Phase 2 | 4 | Canadian Cancer Trials GroupNETWORK | 2 | Feb 22, 2024 | clinicaltrials |
| NCT03573544 | This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | terminated | Phase 1 / Phase 2 | 54 | OBI Pharma, IncINDUSTRY | 2 | Feb 22, 2024 | clinicaltrials |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | terminated | Phase 2 | 63 | Debiopharm International SAINDUSTRY | 23 | Feb 7, 2024 | clinicaltrials |
| NCT04071756 | Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions | terminated | Phase 2 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05430555 | A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors(IMAG1NE) | terminated | Phase 1 / Phase 2 | 23 | T-knife GmbHINDUSTRY | 5 | Feb 7, 2024 | clinicaltrials |
| NCT01311713 | Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 45 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT04465760 | Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy | terminated | Phase 2 | 9 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT02829723 | A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 192 | Novartis PharmaceuticalsINDUSTRY | 8 | Jan 18, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT01190644 | Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors | terminated | Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05920408 | Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Exscientia AI LimitedINDUSTRY | 2 | Nov 8, 2023 | clinicaltrials |
| NCT05255484 | Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 24 | LaNova Medicines LimitedINDUSTRY | 1 | Oct 25, 2023 | clinicaltrials |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04171700 | A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes(LODESTAR) | terminated | Phase 2 | 83 | pharmaand GmbHINDUSTRY | 1 | Oct 2, 2023 | clinicaltrials |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 12 | NBE-Therapeutics AGINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT03926143 | A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies | terminated | Phase 2 | 9 | BayerINDUSTRY | 4 | Aug 4, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | Dracen Pharmaceuticals, Inc.INDUSTRY | 5 | Jun 12, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT00886782 | A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 28, 2023 | clinicaltrials |
| NCT04775680 | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 25 | Adagene (Suzhou) LimitedINDUSTRY | 1 | Apr 24, 2023 | clinicaltrials |
| NCT04696848 | The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 25 | Tae Won KimOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05010525 | A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors(REACH) | terminated | Phase 1 / Phase 2 | 8 | Shanghai Antengene Corporation LimitedINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05008445 | Study of LM-102 in Patients With Advance Solid Tumors | terminated | Phase 1 / Phase 2 | 11 | LaNova Medicines Development Co., Ltd.INDUSTRY | 1 | Mar 9, 2023 | clinicaltrials |
| NCT04518137 | A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH) | terminated | Phase 2 | 5 | Shanghai Antengene Corporation LimitedINDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT04800627 | Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor | terminated | Phase 1 / Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT04372706 | RTX-240 Monotherapy and in Combination With Pembrolizumab | terminated | Phase 1 / Phase 2 | 69 | Rubius TherapeuticsINDUSTRY | 1 | Dec 13, 2022 | clinicaltrials |
| NCT02700308 | A Study of Kyphoplasty and Vertebroplasty in the Treatment of Spine Metastases(KYPHO-01) | terminated | Phase 2 | 31 | Centre Leon BerardOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT02880371 | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 82 | PfizerINDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT03347123 | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | terminated | Phase 1 / Phase 2 | 11 | Incyte CorporationINDUSTRY | 1 | Feb 28, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT01295697 | Study of EZN-2208 Pediatric Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 32 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 13, 2024source: clinicaltrials